Beam Therapeutics Inc.

NASDAQ: BEAM
Share price (3/20/25): $22.87
Market cap (3/20/25): $1.914 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/24 FY 2024

ended 09/30/24 Q3

ended 06/30/24 Q2

ended 03/31/24 Q1

ended 12/31/23 FY 2023

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Free writing prospectus

Prospectus supplement for primary offering

Registration of securities for employees

Automatic shelf registration

Ownership Filter

Cavanagh Bethany J

Bellon Christine

Bellon Christine

ARCH Venture Fund IX, L.P.

News Filter

Announces Pricing of Underwritten Offering

Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-Causing Mutation

Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Announces New Data From BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Scanned paper annual report submission

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC